Stoke Therapeutics Inc (STOK)

04:01 AM

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates - Business Wire

04:01 AM

09:22 AM

Stoke Therapeutics Inc (STOK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

09:22 AM

06:57 AM

Troluce Capital Advisors LLC Buys Shares of 652,800 Stoke Therapeutics, Inc. $STOK - MarketBeat

06:57 AM

06:18 AM

Stoke Therapeutics Inc (STOK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

06:18 AM

04:08 AM

Stoke Therapeutics Inc (STOK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

04:08 AM

Jul 26, 2026

Stoke Therapeutics Inc (STOK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jul 26, 2026

Jul 25, 2026

TradingKey - TradingKey

Jul 25, 2026

Jul 25, 2026

Granahan Investment Management LLC Has $10.93 Million Stock Holdings in Stoke Therapeutics, Inc. $STOK - MarketBeat

Jul 25, 2026

Jul 25, 2026

Stoke Therapeutics, Inc. Revenue Breakdown – NASDAQ:STOK - TradingView

Jul 25, 2026

Jul 24, 2026

Siren L.L.C. Sells 252,000 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat

Jul 24, 2026

Jul 24, 2026

Stoke Therapeutics Inc (STOK) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jul 24, 2026

Jul 23, 2026

(STOK) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Jul 23, 2026

Jul 22, 2026

Stoke Therapeutics (STOK) Edges Higher, Testing Resistance at $30.41ADD Alert - dars.gov.et

Jul 22, 2026

Jul 19, 2026

Stoke Therapeutics Inc (STOK) - MSN

Jul 19, 2026

Jul 19, 2026

Stoke Therapeutics: Its Dravet Syndrome Lead Asset Enters The Last Stretch (NASDAQ:STOK) - Seeking Alpha

Jul 19, 2026

Jul 17, 2026

Stoke Therapeutics Chief Scientific Officer Thomas McCauley files initial beneficial ownership statement - Bitget

Jul 17, 2026

Jul 17, 2026

Form 4 Stoke Therapeutics Inc For: 17 July By Investing.com - Investing.com Nigeria

Jul 17, 2026

Jul 17, 2026

Form 4 Stoke Therapeutics Inc For: 17 July - Investing.com India

Jul 17, 2026

Jul 17, 2026

Stoke Therapeutics (STOK) director gifts 303,190 options to trust - Stock Titan

Jul 17, 2026

Jul 17, 2026

Stoke Therapeutics (STOK) awards 225,000 stock options to Chief Scientific Officer - Stock Titan

Jul 17, 2026

Jul 17, 2026

Stoke Therapeutics (STOK) CSO Thomas McCauley files initial insider report - Stock Titan

Jul 17, 2026

Jul 17, 2026

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)July 16, 2026 - BioSpace

Jul 17, 2026

Jul 16, 2026

Stoke Therapeutics grants CSO McCauley options for 225,000 shares at $29.91 each - Bitget

Jul 16, 2026

Jul 14, 2026

Stoke Therapeutics (NASDAQ:STOK) Rating Increased to Strong-Buy at The Goldman Sachs Group - MarketBeat

Jul 14, 2026

Jul 14, 2026

Stoke Therapeutics (STOK) Declines Slightly as Stock Consolidates Near ResistanceDividend Stock Picks - dars.gov.et

Jul 14, 2026

Jul 13, 2026

Jefferies Initiates Stoke Therapeutics(STOK.US) With Buy Rating, Announces Target Price $44 - Moomoo

Jul 13, 2026

Jul 13, 2026

Stoke Therapeutics appoints Thomas McCauley as CSO By Investing.com - Investing.com India

Jul 13, 2026

Jul 13, 2026

Stoke Tx appoints Thomas McCauley as CSO - The Pharma Letter

Jul 13, 2026

Jul 13, 2026

Stoke Therapeutics Appoints Thomas McCauley as Chief Scientific Officer - citybiz

Jul 13, 2026

Jul 13, 2026

Goldman Sachs initiates Stoke Therapeutics stock with buy rating on Dravet therapy potential - Investing.com UK

Jul 13, 2026

Jul 13, 2026

Stoke Therapeutics Taps Dr. Thomas McCauley as Chief Scientific Officer - Contract Pharma

Jul 13, 2026

Jul 13, 2026

Stoke Therapeutics Announces Appointment of Thomas McCauley as Chief Scientific Officer - marketscreener.com

Jul 13, 2026

Jul 13, 2026

Stoke Therapeutics appoints Thomas McCauley as CSO - Investing.com

Jul 13, 2026

Jul 13, 2026

Goldman Sachs Initiates Coverage on Stoke Therapeutics With Buy Rating, $44 Price Target - marketscreener.com

Jul 13, 2026

Jul 13, 2026

Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer - Business Wire

Jul 13, 2026

Jul 13, 2026

STOK Initiates Coverage On Goldman Sachs -- Price Target Announced at $44 - GuruFocus

Jul 13, 2026

Jul 13, 2026

Goldman Sachs initiates Stoke Therapeutics stock with buy rating on Dravet therapy potential By Investing.com - Investing.com South Africa

Jul 13, 2026

Jul 12, 2026

Candriam S.C.A. Has $16.35 Million Stake in Stoke Therapeutics, Inc. $STOK - MarketBeat

Jul 12, 2026

Jul 12, 2026

Stoke Therapeutics Insiders Sold US$1.3m Of Shares Suggesting Hesitancy - Moomoo

Jul 12, 2026

Jul 10, 2026

Stoke Therapeutics, Inc. Actuals & Estimates (DUS:0GT) - TradingView

Jul 10, 2026

Jul 10, 2026

Analysts Are Bullish on Top Healthcare Stocks: Urogen Pharma (URGN), Stoke Therapeutics (STOK) - The Globe and Mail

Jul 10, 2026

Jul 10, 2026

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Jul 10, 2026

Jul 09, 2026

Stoke Therapeutics Announces Updates to Timelines for the Complet - The National Law Review

Jul 09, 2026

Jul 09, 2026

Needham Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $40 - Moomoo

Jul 09, 2026

Jul 08, 2026

Stoke Therapeutics highlights antisense pipeline as genetic medicine interest grows - AD HOC NEWS

Jul 08, 2026

Jul 07, 2026

Stoke Therapeutics holds the focus. Investors await the next evidence - Ad-hoc-news.de

Jul 07, 2026

Jul 07, 2026

Moran Wealth Management LLC Takes $1.32 Million Position in Stoke Therapeutics, Inc. $STOK - MarketBeat

Jul 07, 2026

Jul 07, 2026

Stoke Therapeutics (STOK) Receives a Buy from Jefferies - The Globe and Mail

Jul 07, 2026

Jul 06, 2026

Stoke Therapeutics (STOK) CMO sells 7,228 shares in planned 10b5-1 trades - Stock Titan

Jul 06, 2026

Jul 05, 2026

Stoke Therapeutics faces earnings test after revenue miss By Investing.com - Investing.com Nigeria

Jul 05, 2026